Evaluation of the effect of subcutaneous adalimumab on the prognosis of patients with COVID-19: a pilot study

Phase 2

Recruiting

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20220112053701N1
• Lead Sponsor: Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Severe COVID-19 (respiratory rate more than 30 per minute or oxygen saturation less than 90% or more than 50% lung parenchyma involvement on the patient's CT scan)
Patient's consent
Age: 60_70 years old

Exclusion Criteria

Fever (body temp above 40°C)
Any active bacterial or fungal infection
Positive blood and urine culture
History of chronic obstructive pulmonary disease
History of tuberculosis
Heart failure
Infectious skin wounds
History of multiple sclerosis
Very severe/critical stage of the disease (shock, encephalopathy, myocardial lesion, coagulation, and renal impairment)
abnormal liver tests in the form of liver enzymes more than 2 times normal
GFR less than or equal to 30

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
C-reactive protein (CRP). Timepoint: First and 5th day. Method of measurement: using latex agglutination tests and a bionic CRP quantitative detection kit.;Lactate Dehydrogenase (LDH). Timepoint: First and 5th day. Method of measurement: routine commercial kits (Pars Azmoon Co.,Iran).;SpO2 level. Timepoint: First and 5th day. Method of measurement: by pulse oximeter.;Respiratory rate per minute. Timepoint: First and 5th day. Method of measurement: Counting the number of breaths for one minute by counting how many times the chest rises.;Hospitalization stay. Timepoint: discharge time. Method of measurement: Counting the number of days hospitalized.